智通财经APP获悉，中泰证券发布研报称，医药作为兼具科技和消费属性的板块，在市场行情的轮动中 将持续呈现结构性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年 初的位置，普遍标的估值合理，因此建议关注所在细分行业(优选小核酸、体内CAR、ADC、二代IO、 protac等)及公司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨 的新方向，除关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能 够中短期内兑现估值弹性的标的。 中泰证券主要观点如下： 把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。 本周沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨 0.22%，化学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、 2.68%。本周医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹 码较轻的部分个股表现亮眼。 该行认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中 ...

【瑞博生物】电话会小结 – 与Madrigal达成BD，6千万美元首付款+43亿美元里程碑【东吴医药朱国广团队】 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画，瑞博具备临床前到临床的转化经验和数据，因此可以倒算出临床前的数据要求，完全符合 要求，因此达成了合作。 ②MDRL已经是MASH领域先行者，MDRL拥有Rezdi ④对瑞博来说，MASH临床前数据优秀，但是并不是公司临床聚焦的方向，临床也很难做，最优解就是合作授 权。 ⑤达成合作的6个管线，并不相同，具有互补机制。 #未来2年内至少达到一个mash的IND，或有数kw美元的收入。 与BI的合作：BI与MDGl的靶点、适应症领域均有区别，BI更注重晚期肝病和并发症，聚焦FIC的科学突破性创新 靶点。 目前进展符合预期，已经拿到2个里程碑，预计与MDGL的合作管线同期会进入IND。 创新技术：肾靶向领先全球 + 其他的肝外递送早期资产 + 双靶点。 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画， ...

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

Group 1: Gold and Silver Market Outlook - A Reuters survey indicates that gold prices are expected to reach a new high of $4,746.50 per ounce by 2026, driven by geopolitical uncertainties and strong central bank purchases, marking a significant increase from last year's forecast of $4,275 [1] - The average price expectation for silver in 2026 has also been raised to $79.50 per ounce, up from $50 in the previous year's survey [1] Group 2: Currency and Economic Analysis - The strong US dollar is exerting downward pressure on gold and silver prices, with analysts suggesting that if the dollar's rebound continues, it may further impact gold prices negatively [2] - UBS forecasts a 10% increase in global stock markets by the end of the year, with a focus on diversification into markets like China, Japan, and Europe, driven by strategic autonomy and fiscal expansion [3] - Mitsubishi UFJ reports that the Japanese yen has fallen to a near two-week low due to election expectations, with potential for continued selling pressure as confidence in the ruling party's stability grows [4] - Goldman Sachs warns of upward fiscal risks in Japan ahead of the upcoming elections, suggesting that unless the Bank of Japan accelerates interest rate hikes, the yen may weaken further [6] Group 3: Sector-Specific Insights - Zhongtai Securities expresses a positive outlook on the raw material pharmaceutical sector, highlighting innovations in small nucleic acids and ADC toxins as catalysts for growth [7] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts, as rising raw material prices are expected to pressure profit margins in the first quarter of 2026 [8] - Galaxy Securities identifies two main paths for AI-driven benefits: enhancing platform efficiency and improving production efficiency through content and tools, suggesting a focus on internet stocks and AI-related applications [9]

Group 1 - Current U.S. financial market conditions do not support the initiation of balance sheet reduction, as liquidity pressures have only recently eased and reserve levels remain limited [1] - The Federal Reserve's asset holdings are approximately 20% of GDP, nearing pre-pandemic levels, indicating a constrained liquidity environment [1] - If the proposed balance sheet reduction is implemented quickly under a new Federal Reserve chair, it may lead to renewed liquidity pressures in the U.S. financial markets [1] Group 2 - The supply-demand situation for traditional electronic fabrics, particularly the 7628 electronic fabric, is expected to remain tight through 2026, with price increases likely exceeding market expectations [2] - Prices for 7628 electronic fabric could reach over 6 yuan per meter, indicating significant upward price potential [2] Group 3 - The raw material pharmaceutical sector is strategically favored, with innovative drug segments such as small nucleic acids, peptides, and ADC toxins driving continuous industry chain catalysts [3] - Many companies in the sector are at a turning point, with existing business stabilizing and new business opportunities expected to emerge [3] - Following several years of price declines, the raw material and intermediate industry is anticipated to see price improvements due to rising commodity and upstream chemical prices [3]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 财通证券发布研报称，化学原料药PPI长期承压，行业经历低谷。随着上游成本上涨、政策驱动出清， 以及GLP-1口服小分子、小核酸等新药产业化趋势成熟，头部原料药企业凭借卡位MNC供应链的核心优 势，有望从周期股转向创新产业链，开启第二增长曲线。 财通证券主要观点如下： 化学原料药PPI指数长期承压 过去几年，原料药行业经历了艰难时期。各类产品价格下跌，其中沙坦类、肝素类、动保类等价格已跌 至历史低位，部分龙头企业甚至处于亏损阶段。同时，集采对化药制剂的降价效应逐渐传递到上游原 料，而致原料药利润率不断下降。化学原料药PPI指数长期承压。 原料药企业有望开启第二增长曲线 投资建议：关注头部中间体、原料药及CDMO企业，建议关注诚达药业、联化科技、药明康德、凯莱 英、九州药业、奥锐特、天宇药业、康龙化成、博腾股份等。 风险提示：商业化不及预期的风险；贸易摩擦的风险；产能提升不及预期的风险。 原材料价格及汇率上涨，反内卷政策有望驱动原料药行业加速出清，同时，新兴产业趋势走向成熟，原 料药企业有望开启第二增长曲线。由于石油化工相关上游原料价格有上 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].

Core Viewpoint - By 2025, China's innovative pharmaceuticals are expected to demonstrate significant global competitiveness, with record overseas transactions and many companies turning profitable [1][2]. Domestic Review - The global competitiveness of Chinese innovative drugs is highlighted, with a record-breaking overseas transaction total exceeding $135 billion in 2025, and upfront payments reaching $7 billion. The average deal size has increased from $600 million to $900 million [2]. - A comprehensive support system from policy, including review and approval processes to medical insurance payments, is being established, leading to a rapid increase in market share for innovative drugs, particularly in oncology and immunology, which now exceeds 32% [2]. - Companies like BeiGene and Innovent Biologics have already turned profitable, with others like CanSino Biologics and Zai Lab expected to follow suit in the next three years, indicating a positive cycle of capital influx, R&D iteration, and value realization [2]. Overseas Review - The S&P Biotechnology Index has risen over 50% from its bottom in the second half of 2025, driven by interest rate cuts that have shifted funds from tech stocks to biotech [3]. - Major pharmaceutical companies (MNCs) are actively pursuing mergers and acquisitions to supplement their pipelines, particularly in oncology and immunology, as they face a "patent cliff" with key drugs like Keytruda and Opdivo losing patent protection by 2027-2028 [3]. Assessment - Chinese companies are becoming significant partners for the top 20 MNCs, with Chinese transaction amounts accounting for 40% of the global innovative drug market. China is transitioning from a "fast-follower" to a "smart-innovator" in fields like PD-1 bispecific antibodies, ADCs, and small nucleic acids, leading in pipeline numbers and clinical progress [4]. - The speed and cost advantages of Chinese innovative drug companies are notable, with patient recruitment occurring at 2-5 times the speed of international counterparts and costs being half that of Western companies [4]. Key Tracks and Investment Opportunities - Bispecific antibodies are expected to surpass $120 billion in global sales, with Chinese companies leading the development of second-generation IO products [5]. - ADCs are seeing significant contributions from China, with over half of the global pipeline, and are expected to achieve proof of concept (POC) validation by 2026 [5]. - Combination therapies in oncology are showing synergistic effects, with key clinical data expected in 2026 [5]. - The market for iRAS inhibitors is projected to exceed $8 billion in the U.S., with critical breakthroughs anticipated in 2026 [5]. - Small nucleic acids are expanding into broader applications, with key products expected to commercialize and deliver critical data in 2026 [5]. - Protein degradation technologies are advancing rapidly, with numerous autoimmune disease targets expected to yield data in 2026 [5]. - The metabolic and cardiovascular fields are also poised for breakthroughs, with new targets addressing issues like muscle loss associated with GLP-1 therapies [5]. Main Lines and Recommended Focus - Recommended companies in the bispecific antibody space include CanSino Biologics, Innovent Biologics, and others [7]. - ADC-focused companies include I-Mab, Kelun-Biotech, and others [7]. - Small nucleic acid companies to watch include Ribobio, BIBO, and others [7]. - Strategic combinations to consider include CanSino Biologics, BeiGene, and others [8]. - Flexible combinations include BIBO, Eifang Biologics, and others [8]. - Stable combinations include Hengrui Medicine, China National Pharmaceutical Group, and others [8].

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

Core Viewpoint - The Shanghai Municipal Committee emphasizes the importance of strengthening the research and development of innovative drugs and medical devices, focusing on new drug targets, accelerated results transformation, improved clinical trial efficiency, and innovative payment methods to promote the high-end and efficient development of the biopharmaceutical industry [1] Group 1: Investment Opportunities - Jianghai Securities predicts that 2026 will see a surge in BD transactions and mergers in the innovative drug sector, highlighting three main investment themes: focusing on ADC, bispecific antibodies, and RDC tracks, selecting globally competitive innovative drug companies, and paying attention to the commercialization and BD progress of late-stage pipelines [1] - The second investment theme involves closely following cutting-edge fields like small nucleic acids, targeting leading companies with proprietary delivery platforms and chronic disease pipelines [1] - The third theme looks favorably on supporting companies in the innovative drug industry chain, such as CXO firms that will benefit from increased R&D investment and accelerated international expansion, as well as niche companies deeply engaged in industry chain integration that hold long-term value [1] Group 2: Market Trends - Guosen Securities notes that the Chinese innovative drug industry has shown a long-term positive development trend, particularly evident in the explosive growth of BD transactions in recent years [1] - It is important to recognize that for most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners in overseas development and subsequent global clinical data readings further enhancing the certainty of product commercialization in the global market [1]